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Abstract
Background: Several studies have analyzed arrhythmias in patients with pulmonary hyper-
tension (PH) and increased P-wave duration was identified as a risk factor for development of 
atrial fibrillation (AF).
Methods: We retrospectively analyzed the incidence of arrhythmias in patients with an initial 
diagnosis of PH during long-term follow-up and assessed the prognostic value of electrocardio-
graphy (ECG) data. Data from 167 patients were analyzed (Dana Point Classification: Group 1: 
59 patients, Group 2: 28 patients, Group 3: 39 patients, Group 4: 41 patients). Clinical, 6-min-
ute walk distance test, echocardiography and right heart catheterization data were collected, 
and baseline/follow-up ECGs were analyzed.
Results: Baseline ECGs revealed sinus rhythm in 137 patients. Thirteen patients had newly 
onset AF during follow-up. In 30 patients, baseline ECG showed AF. Patients with baseline 
AF showed higher atrial diameters and higher right atrial pressure. Patients with P-wave du-
ration > 0.11 s had shorter survival. Other ECG parameters (PQ-interval, QRS-width, QT-/ 
/QTc-interval) were not associated with survival. Mean survival times were 79.4 ± 5.4 months 
(sinus rhythm), 64.4 ± 12.9 months (baseline AF) and 58.8 ± 8.9 months (newly onset AF 
during follow-up) (p = 0.565).
Conclusions: Atrial fibrillation predict adverse prognosis in patients with PH and a longer 
P-wave (> 0.11 s) is associated with shorter survival time. (Cardiol J 2016; 23, 4: 465–472)
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Introduction
Pulmonary hypertension (PH) is defined as 
an increase of ≥ 25 mm Hg in mean pulmonary 
arterial pressure (mPAP), as well as pulmonary 
capillary wedge pressure (PCWP) £ 15 mm Hg or 
> 15 mm Hg in precapillary (Groups 1, 3, 4) and 
postcapillary (Group 2) forms, respectively. The 
increase in pulmonary vascular resistance leads to 
an increase in the afterload on the right ventricle, 
resulting in dilation of the right atrium and ventri-
cle and vascular remodeling [1–4].
Five studies evaluated the incidence of atrial 
arrhythmias in patients with PH [5–9]. The cumu-
lative incidence varied between 11.7% and 25.1% 
over periods of 6–13 years.
Electrophysiological studies have shown that 
in patients suffering from PH, there is a reduction 
in regional conduction velocity in the right atrium 
and an increase in the number of areas with low 
voltage and electrical silence [10]. A few stud-
ies analyzed P-wave duration, which reflects the 
electrical activation of the atria and its impact on 
the development of arrhythmias [11–13]. These 
studies found that P-wave duration is higher in 
patients developing atrial fibrillation (AF).
This study was performed to elucidate the in-
cidence of arrhythmias during long-term follow-up, 
the prognostic value of electrocardiogram (ECG) 
for arrhythmias and the influence of different ECG 
parameters on survival in patients with newly 
detected PH.
Methods
Data of patients with first detection of PH 
were analyzed retrospectively. The following data 
were extracted from patients’ medical records: 
demographic data, etiology of PH, anti-arrhythmic 
medication, baseline and follow-up ECGs, data from 
echocardiography and right heart catheterization. 
The study and the study design were approved by 
the institutional Review Board (reference number: 
106/13). All patients were followed in our outpa-
tient clinic for PH.
Electrocardiogram
Twelve-lead ECGs with patients in supine 
position were performed by trained technicians and 
reviewed by two physicians blinded to the clinical 
characteristics and outcome of the patients. Com-
mercially available ECG devices (Model Schiller 
AT-10 plus; Schiller AG, Baar; Switzerland) were 
used for ECG recordings (paper speed = 50 mm/s; 
sensitivity of 10 mm/mV). ECG was recorded from 
all patients on the first visit (baseline ECG) and at 
follow-ups in our outpatient clinic. Heart rate and 
rhythm, P-wave-, PQ-, QRS- and QT(c)-duration 
and axis of QRS were included in the evaluation. 
ECG variables were analyzed with standard ECG 
nomenclature and definitions [14, 15]. For each 
ECG variable, we defined ranges and analyzed the 
correlation with mortality.
Echocardiography
Transthoracic echocardiography was per-
formed using a GE Vivid S 6 (GE, Germany). The 
following diameters and valves were measured: 
left atrial diameter (edge-to-edge method, par-
asternal long axis view), right atrial diameter 
(4-chamber view, measured at end-systole), right 
ventricular diameter (4-chamber view, measured 
at end-diastole), tricuspid annular plane systolic 
excursion (TAPSE) and systolic pulmonary artery 
pressure.
All measurements were carried out in accord-
ance with the guidelines of the American Society 
of Echocardiography [16–20].
Right heart catheterization
Right heart catheterization was performed via 
the right jugular vein. Hemodynamic measurements 
included mean right atrial pressure (mRAP), mPAP, 
PCWP, pulmonary vascular resistance (PVR), sys-
temic vascular resistance, cardiac index (thermodi-
lution) and venous saturation (ven sO2).
Statistical analysis
Statistical calculations were performed using 
SPSS (ver. 21; IBM, Armonk, NY). Patient data are 
presented as absolute numbers (mean or median) 
and standard deviation (SD) or interquartile range 
(IQR). Comparisons between groups were made 
using the t-test or c2 test, as appropriate. P-values 
of < 0.05 were considered statistically significant.
The endpoint was all-cause mortality. Cox 
regression analyses were performed to evaluate 
the influence of P-wave-, PQ-, QRS- and QT(c)-du-
ration on survival. Multivariate Cox regression was 
used to adjust for possible confounders, i.e. age, 
gender, 6-minute walk distance, and PVR. These 
parameters were assessed with hazard ratios (HR) 
of single and multivariate Cox proportional hazards 
analyses and are given as point estimates and 95% 
confidence intervals (CI).
Kaplan-Meier plots were used to illustrate sur-
vival in relation to P-wave duration and incidence 
of cardiac arrhythmias. Statistical analyses were 
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performed using data obtained during the entire 
observation period (up to 10 years), however the 
presentation of longitudinal survival data covers 
only 5 years, because the data after this time point 
were too limited.
Results
One hundred and sixty-seven patients were 
included into the analyses. Mean age was 61.5 ± 
± 14.4 years (range 19–84). Patients suffered from 
various forms of PH: pulmonary arterial hyperten-
sion (Group 1: 59 patients; idiopathic pulmonary 
arterial hypertension [IPAH], n = 33, connective 
tissue disease [CTD], n = 19, congenital heart dis-
ease [CHD], n =7), PH associated with left heart 
disease (pulmonary venous hypertension [PVH]; 
Group 2: 28 patients), PH associated with lung dis-
ease (Group 3: 39 patients; chronic obstructive pul-
monary disease [COPD], n = 16, interstitial lung 
disease [ILD], n = 23) and chronic thromboem-
bolic pulmonary hypertension (CTEPH, Group 4: 
41 patients).
When baseline ECGs were recorded, patients 
were using beta-blockers (n = 42), calcium chan-
nel blockers (n = 35) or digitalis as antiarrhythmic 
medication (n = 13), and 17 patients had a cardiac 
pacemaker which had been fitted to manage brad-
yarrhythmia (Table 1).
Electrocardiogram
The mean heart rate was 79 ±17 bpm (range: 
45–124). The P-wave duration was 0.1 ± 0.02 s, 
and the PQ-interval was 0.17 ± 0.03 s. Mean 
QRS-width was 0.1 ± 0.02 s, the QT-interval was 
0.38 ± 0.05 s (range: 0.20–0.53) and corrected QT 
interval (QTc) = 0.41 ± 0.04 s. Baseline ECGs 
revealed sinus rhythm (SR) in 137 (82%) patients 
and AF in 30 (18%, age 68.9 ± 9.8 years) patients. 
During follow-up, ECGs revealed SR in 124 (age 
58.6 ± 16.3 years) patients and newly onset AF 
in 13 (7.8%; age 68.3 ± 11.2 years) patients. The 
P-waves in these patients were normal before onset 
of AF. In the baseline ECG, AF was most common 
in patients in PH Group 2 (16/28 patients, Table 2). 
Thirty-eight (88.4%) patients with AF (in baseline 
ECG or newly onset during follow-up) were treated 
with anticoagulants.
P-wave duration was 0.11 ± 0.02 s (median: 
0.11 s) in patients with SR in the baseline ECG 
and at follow-up, whereas patients with SR in 
the baseline ECG and AF at follow-up presented 
a P-wave duration of 0.10 ± 0.02 s (median: 0.10 s); 
there was no difference in P-wave duration related 
to ECG at follow-up (p = 0.193). The morphology 
of the P-wave was normal in 111 (66.5%) patients. 
Table 1. Baseline characteristics of patients.
All patients n = 167
Gender (female/ 
/male)
n = 89 (53.3%)/ 
n = 78 (46.7%)
Age [years] 61.5 ± 14.4
Medication BB: n = 42 (25.1%)
CCB: n = 35 (21.0%)
BB and CCB: n = 7 (4.3%)
Digitoxin/Digoxin: n = 13 (7.8%)
BB — beta-blocker; CCB — calcium channel blocker
Table 2. Pulmonary hypertension (PH) subgroups and heart rhythm.
PH-Group PH-Subgroup Arrhythmias (n/%)
Sinus rhythm (baseline 
ECG + follow-up,  
n = 124)
AF (baseline ECG,  
n = 30)
AF during follow-up  
(n = 13)
1 IPAH (n = 33) 27 (81.8%) 4 (12.1%) 2 (6.1%)
CTD (n = 19) 14 (73.6%) 1 (5.3%) 4 (21.1%)
CHD (n = 7) 5 (71.4%) 1 (14.3%) 1 (14.3%)
2 PVH (n = 28) 11 (39.3%) 16 (57.1%) 1 (3.6%)
3 ILD (n = 23) 18 (78.3%) 4 (17.4%) 1 (4.3%)
COPD (n = 16) 14 (87.5%) 0 (0%) 2 (12.5%)
4 CTEPH (n = 41) 35 (85.4%) 4 (9.8%) 2 (4.8%)
ECG — electrocardiogram; AF — atrial fibrillation; IPAH — idiopathic pulmonary arterial hypertension; CTD — connective tissue disease;  
CHD — congenital heart disease; PVH — pulmonary venous hypertension; ILD — interstitial lung disease; COPD — chronic obstructive  
pulmonary disease; CTEPH — chronic thromboembolic pulmonary hypertension
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In 26 (15.5%) patients, ECG revealed an increased 
amplitude of the P-wave.
The most common axis types were normal 
(n = 105; 62.8%). Right axis deviation was found 
in 39 (23.4%) patients and left axis deviation in 
23 (13.8%) patients.
Extrasystoles (ES) were rare, the baseline ECG 
revealed supraventricular ES in 11 (4.7%) patients 
and ventricular ES in 13 patients (range 1–3/ECG).
Subgroup analysis of the ECG parameters did 
not reveal clinically relevant differences. Statisti-
cal significance was found for the following ECG 
parameters: P-wave duration: IPAH vs. PVH (p = 
= 0.004), CTD vs. PVH (p = 0.007), CHD vs. PVH 
(p = 0.032), COPD vs. PVH (p = 0.026), IPAH vs. 
ILD (p = 0.02), CTD vs. ILD (p = 0.029); PQ-inter-
val: IPAH vs. CTD (p = 0.037), QRS-width: CTD 
vs. CTEPH (p = 0.032), QT-interval: IPAH vs. ILD 
(p = 0.009), IPAH vs. COPD (p = 0.001), CTD 
vs. PVH (p = 0.039), ILD vs. PVH (p = 0.001), 
COPD vs. PVH (p < 0.001), CTEPH vs. PVH 
(p = 0.047), CHD vs. COPD (p = 0.011) and QTc-
-interval: IPAH vs. COPD (p = 0.007) (Table 3).
Six-minute walk test
One hundred and thirty-two patients under-
went a 6-minute walk test; the remaining patients 
were unable to walk owing to their clinical state. 
Patients walked 303 ± 120 m in 6 min. The mean 
walking distance was 305 ± 124 m for patients with 
SR in the baseline ECG, 284 ± 112 m for patients 
with newly onset AF during follow-up, and 305 ± 
± 108 m for patients with AF in the baseline ECG. 
The differences were without statistical signifi-
cance (p = 0.881).
Hemodynamic parameters evaluated  
by echocardiography and right heart  
catheterization
Cardiac function and hemodynamic param-
eters were evaluated with echocardiography and 
right heart catheterization. The diameters of the 
right and left atria were elevated in patients with 
AF in baseline ECG (baseline SR vs. baseline AF: 
right atrium: p = 0.279, left atrium: p < 0.0001; 
baseline AF vs. newly onset AF during follow-up: 
right atrium: p = 0.175, left atrium: p = 0.008). 
Right heart catheterization revealed highest RAP 
in patients with baseline AF (baseline SR vs. base-
line AF: p = 0.288; baseline AF vs. newly onset AF 
during follow-up: p = 0.549; follow-up SR vs. AF 
during follow-up: p = 0.044) (Table 4).
Mortality (n = 148)
Survival data were available for 148 patients 
(113 patients SR during follow-up, 9 patients with 
newly onset AF during follow-up, 26 patients with 
AF in baseline ECG). ECG parameters (P-wave-
duration, PQ-interval, QRS-width, QTc-interval) 
were divided into range categories (Tables 5, 6) for 
analysis of survival. SR in the baseline ECG (and 
therefore possibility for interpretation of P-wave 
duration and PQ-interval) was recorded in 122 pa- 
tients. QRS-width and QT-/QTc-intervals were 
analyzed in all patients (n = 148).
Mortality and ECG parameters
Patients with short P-waves (< 0.1 s) showed 
improved survival rates compared to patients with 
long P-waves (> 0.11 s) (Table 5). Univariate Cox 
regression analysis showed a significant associa-
Table 3. Pulmonary hypertension (PH) subgroups and electrocardiography-parameters.
PH-Group P-wave  
duration [s]
PQ-interval  
[s]
QRS-width  
[s]
QT-interval  
[s]
QTc-interval  
[s]
Idiopathic pulmonary arterial  
hypertension
0.10 ± 0.0.2 0.18 ± 0.03 0.10 ± 0.02 0.39 ± 0.04 0.42 ± 0.03
Connective tissue disease 0.10 ± 0.01 0.16 ± 0.02 0.09 ± 0.02 0.38 ± 0.06 0.42 ± 0.05
Congenital heart disease 0.10 ± 0.01 0.17 ± 0.01 0.10 ± 0.02 0.42 ± 0.07 0.42 ± 0.06
Pulmonary venous hypertension 0.12 ± 0.03 0.16 ± 0.03 0.09 ± 0.01 0.39 ± 0.02 0.43 ± 0.04
Interstitial lung disease 0.11 ± 0.01 0.17 ± 0.02 0.09 ± 0.02 0.37 ± 0.03 0.41 ± 0.03
Chronic obstructive  
pulmonary disease
0.10 ± 0.01 0.16 ± 0.03 0.10 ± 0.02 0.35 ± 0.04 0.39 ± 0.03
Chronic thromboembolic PH 0.11 ± 0.02 0.17 ± 0.03 0.10 ± 0.02 0.38 ± 0.04 0.41 ± 0.03
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Table 4. Echocardiography and right heart catheterization data.
Parameter Sinus rhythm  
(baseline ECG,  
n = 124)
AF (baseline ECG,  
n = 30)
AF during  
follow-up  
(n = 13)
Echocardiography
Right atrium diameter [mm] 53 ± 10 58 ± 12 51 ± 7 
Left atrium diameter [mm] 38 ± 7 46 ± 5 38 ± 7 
Right ventricle diameter [mm] 42 ± 8 46 ± 11 50 ± 12 
TAPSE [mm] 18 ± 5 15 ± 5 19 ± 4
Systolic pulmonary arterial pressure [mm Hg] 63 ± 25 64 ± 17 64 ± 26 
Right heart catheterization 
Mean pulmonary arterial pressure [mm Hg] 43 ± 15 40 ± 9 39 ± 13 
Right atrial pressure [mm Hg] 7 ± 5 10 ± 6 5 ± 4
Cardiac index [L/min/m2] 2.4 ± 0.6 2.4 ± 0.8 2.6 ± 0.7 
Cardiac output [L/min] 4.5 ± 1.2 4.7 ± 1.7 4.6 ± 1.1 
venous oxygen saturation [%] 65 ± 8% 64 ± 7 64 ± 6
Pulmonary vascular resistance [dyn × s × cm–5] 526 [IQR 615] 442 [IQR 259] 569 [IQR 364]
ECG — electrocardiogram; AF — atrial fibrillation; TAPSE — tricuspid annular plane systolic excursion; IQR — interquartile range
Table 5. P-wave duration and survival.
P-wave-duration [s] Estimated survival rate [as %] Mean survival 
[months]
Deaths [n]
1 year 3 years 5 years
< 0.1 (n = 60) 89.7 81.0 70.2 88.1 ± 6.7 24
0.1–0.11 (n = 24) 81.8 67.4 61.8 62 ± 9.4 9
> 0.11 (n = 38) 77.4 55.8 42.1 49 ± 5.8 19
Table 6. Electrocardiography (ECG) parameters and survival.
ECG-parameter [s] Estimated survival rate [as %] Mean survival 
[months]
Deaths [n]
1 year 3 years 5 years
PQ < 0.16 (n = 65) 85.4 68.5 63.0 80.5 ± 7.1 27
PQ 0.16–0.17 (n = 16) 75.0 62.5 37.5 50.5 ± 10.4 10
PQ > 0.17 (n = 41) 92.1 84.0 65.7 78.9 ± 7.5 15
QRS < 0.09 (n = 64) 87.7 70.7 57.4 78.2 ± 7.6 25
QRS 0.09–0.1 (n = 39) 81.1 69.9 58.5 67.3 ± 7.5 18
QRS > 0.1 (n = 45) 80.8 65.9 57.7 75.7 ± 8.5 19
QT < 0.36 (n = 57) 81.5 68.5 58.3 74.4 ± 7.5 27
QT 0.36–0.4 (n = 46) 90.4 72.8 61.3 79.8 ± 7.4 16
QT > 0.4 (n = 45) 77.6 60.5 53.7 70.4 ± 8.9 19
QTc < 0.40 (n = 51) 84.9 71.1 55.9 73.1 ± 8.0 22
QTc 0.40–0.43 (n = 42) 82.1 71.1 51.3 64.9 ± 8.5 23
QTc > 0.43 (n = 55) 84.3 73.5 65.8 88.7 ± 7.7 17
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tion between duration of the P-wave and survival 
(HR = 2.04, 95% CI: 1.10-3.79, p = 0.024) (dura-
tion < 0.1 s vs. > 0.11 s). In a multivariate anal-
ysis, this association was borderline significant 
(p = 0.060) when age was included as a covariate 
(SR at baseline and follow-up: age 61 ± 15 years; SR 
at baseline and AF at follow-up, age 68 ± 11 years; 
AF at baseline: age 70 ± 8 years). None of the other 
ECG parameters were associated with survival.
Data relating the other ECG parameters (PQ; 
QRS; QT; QTc) to survival are shown in Table 6. 
There was no correlation between duration of 
the intervals and survival (PQ: p = 0.121; QRS: 
p = 0.984; QT: p = 0.482; QTc: p = 0.128).
Mortality and heart rhythm
Electrocardiogram of analyzed patients showed 
SR during follow-up in 113 patients, AF in the 
baseline ECG in 26 patients and newly onset AF 
during follow-up in 9 patients. Forty-two percent of 
the patients (n = 62) died during follow-up. Their 
basic rhythm situation was distributed as follows: 
48 showed SR during follow-up, 10 patients had AF 
in the baseline ECG, and 4 showed newly onset AF 
during follow-up. Mean survival from diagnosis was 
79.4 ± 5.4 months vs. 64.4 ± 12.9 months vs. 58.8 ± 
± 8.9 months; p = 0.565).
Multivariate analysis revealed that age con-
founded the association between onset or preva-
lence of arrhythmias and survival (Fig. 1).
To match our results with other studies [5, 6, 
9] we investigated survival in patients (n = 100) 
of PH Groups 1 and 4. Survival data were available 
for 84 patients and 31 (37%) of them died during 
follow-up. Survival was distributed as follows: pa-
tients with SR 93.3 ± 6.2 months, patients with AF 
in baseline ECG 58.6 ± 21.2 months and patients 
with newly onset AF during follow-up 52.6 ± 13.6 
months (p = 0.151).
Correspondent to the analysis of all patients 
(n = 148), multivariate analysis revealed age as 
a confounder for the association between onset or 
prevalence of arrhythmias and survival (Fig. 2).
Discussion
The incidence and prognostic relevance of ar-
rhythmias during follow-up in patients with PH has 
been evaluated in three studies [5, 6, 9]. Similar 
to these studies, we found only supraventricular 
arrhythmias in this patient population, however 
only 7.8% of our patients developed AF during 
follow-up (Tongers: 11.7%; Olsson: 20.8%; Wen: 
14.3%). This finding is noteworthy due to the fact 
that our patients were older than those in the 
other studies cited (mean age: Olsson: 55 years; 
Tongers: 48 years; Wen: 39 years) [5, 6, 9] and it 
is well-known that the prevalence of AF increases 
with age, from 0.5% at 40–50 years, to 5-15% at 
80 years [20]. Nevertheless, our subgroup analysis 
Figure 1. Heart rhythm and survival. Figure 2. Heart rhythm and survival (patients of pulmo-
nary hypertension Group 1 and Group 4).
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revealed that patients with AF in the baseline ECG 
or during follow-up were older than patients with 
SR (AF in baseline ECG: 70 ± 8.5 years, newly 
onset AF during follow up: 68 ± 11 years and SR 
during follow-up: 61 ± 15 years, respectively; 
baseline AF vs. SR: p = 0.002, newly onset AF 
during follow-up vs. SR: p = 0.110), however there 
was no age difference between patients who had 
AF at baseline and those who developed AF dur-
ing follow-up (p = 0.705). Mean survival time was 
shorter in patients with AF but this effect was not 
statistically significant.
Rottlaender’s et al. study [8] revealed reduced 
TAPSE in patients with evidence of AF. These 
results are consistent with our study, which found 
reduced TAPSE in patients with AF in baseline 
ECG (15 ± 5 mm) compared with those with SR 
in the baseline ECG (18 ± 5 mm). Patients who 
developed AF during follow-up had similar TAPSE 
to patients with SR. Taking into consideration the 
study of Forfia et al. [21] which analyzed prognostic 
relevance of TAPSE in patients with PE, reduction 
of TAPSE in our patients could be an explanation 
of shorter survival in patients with AF in baseline 
ECG (and reduced TAPSE).
The same as Wen et al. [9] we found that right 
ventricular diameter was the only parameter that 
was elevated in patients with AF at baseline and 
during follow-up (p = 0.222). Further parameters 
known to be increased in patients with PH and ar-
rhythmias are RAP and PVR [5, 8, 9]. Interestingly, 
in our study, RAP in patients who developed AF 
during follow-up (7 ± 5 vs. 5 ± 4 mm Hg) was lower 
than in other studies. The increase in PVR was 
without clinical relevance (follow-up AF: 526 dyn × 
s × cm–5; SR: 569 dyn × s × cm–5). Interpretation 
of these results should take into consideration that 
our data for right heart catheterization are baseline 
data, and do not permit the detection of a progres-
sive increase in RAP or PVR before onset of AF 
during follow-up. As in other studies, raised RAP 
and PVR seem to be risk factors for arrhythmias 
in patients with PH.
The prognostic value of various ECG param-
eters has been analyzed in multiple studies. In 
a study which was controlled for variance in age 
and gender, increased P-wave duration was identi-
fied as a risk factor for development of AF [12, 13]. 
Genovesi et al. [11] investigated P-wave duration 
in hemodialysis patients with and without AF and 
reported that P-wave duration was longer (153 
± 16 ms) in patients with a history of AF than in 
patients without AF. These results are not directly 
comparable with ours, as unlike our sample many of 
their patients suffered from reduced left ventricular 
function and left ventricular hypertrophy. We found 
no difference in P-wave duration between patients 
with and without AF during follow-up. Sun et al. 
[22] analyzed QRS width in the initial 12-lead ECG 
in 212 patients with idiopathic PH; an increase 
≥ 0.12 s, which was observed in 16.5% of patients, 
was shown to be an independent predictor of mor-
tality; it was associated with a 2.5 times greater 
risk of death. In their study, QRS prolongation was 
positively correlated with right atrium and right 
ventricle diameters suggesting that right ventricu-
lar overload may play a role in the pathogenesis of 
PH. Hemodynamic variables were similar in the 
two groups (Group 1: QRS < 120 ms and Group 2: 
QRS ≥ 120 ms): mRAP (Group 1: 7.4 ± 5.9 mm Hg; 
Group 2: 8.6 ± 7.8 mm Hg; p = 0.30), mPAP (Group 1: 
61.1 ± 16.1 mm Hg, Group 2: 60.9 ± 18.7 mm Hg; 
p = 0.53) and PVR (Group 1: 17 ± 10.3 Wood 
units, Group 2: 18.5 ± 9.8 Wood units; p = 0.69). 
In our study, patients in the longest QRS duration 
category (> 0.1 s) survival times were not shorter 
than for other patients, although atrial diameter 
and PVR were lower.
There have been two studies comparing dura-
tion of the QTc-interval in controls and patients 
with different types of PH [23, 24]. The QTc inter-
val was longer in patients with PH than in controls 
(Hong-Liang’s study, severe PH: 428.6 ± 32.8 ms, 
mild to moderate PH: 423.1 ± 30.2 ms; controls: 
411.1 ± 28.4 ms; criteria for mild to moderate PH: 
mPAP ≥ 25 mm Hg and < 60 mm Hg, criteria for 
severe PH: mPAP ≥ 60 mm Hg) [23]. In Rich’s et al. 
study [24], the QTc interval was 454.8 ± 29 ms in 
patients with PH compared with 429 ± 18 ms in 
controls. The mPAP of our patients was lower than 
in the comparable group in Hong-Liang’s study (pa-
tients with mild-to-moderate PH) and lower than 
in Rich’s study. Rich’s sample clearly had higher 
pulmonary vascular resistance than our sample, 
and Hong-Liang did not provide these data [23, 24]. 
The shorter QTc interval in our patients may have 
been due to lower dilatation of the right ventricle. 
Hong-Liang did not give echocardiographic data 
and only approximately 10% of the PH patients 
(24/202) in this study underwent cardiac mag-
netic resonance imaging, which revealed reduced 
systolic function and markedly higher mean right 
ventricular volume and mass.
Limitations of the study
Our study is not free of limitations. The retro-
spective design may have led to an underestima-
tion of the incidence of arrhythmias because the 
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ECGs were taken periodically and cardiac rhythm 
was only monitored for a few seconds each time, 
therefore self-limiting episodes of arrhythmia may 
have been missed. Echocardiographic and right 
heart catheterization data were not available for 
the follow-up period. The study sample contained 
patients in all PH groups except Group 5, and 
compared to other studies Group 2 was over-rep-
resented, which makes it difficult to compare our 
results with the other published studies in which 
most of the patients were in PH Groups 1 and 4.
Conclusions
Atrial fibrillation predicts adverse prognosis in 
patients with PH, and a longer P-wave (> 0.11 s) 
is associated with shorter survival time. This as-
sociation is confounded by age and is therefore 
important for younger patients suffering from 
pulmonary hypertension.
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